151 related articles for article (PubMed ID: 9607055)
1. Polyvalent vaccination against hepatitis B surface and core antigen using a dicistronic expression plasmid.
Wild J; Grüner B; Metzger K; Kuhröber A; Pudollek HP; Hauser H; Schirmbeck R; Reimann J
Vaccine; 1998 Feb; 16(4):353-60. PubMed ID: 9607055
[TBL] [Abstract][Full Text] [Related]
2. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
Li L; Tian YJ; Shen H; Zhao XP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
[TBL] [Abstract][Full Text] [Related]
3. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes.
Kuhröber A; Wild J; Pudollek HP; Chisari FV; Reimann J
Int Immunol; 1997 Aug; 9(8):1203-12. PubMed ID: 9263018
[TBL] [Abstract][Full Text] [Related]
4. Polyvalent DNA vaccines with bidirectional promoters.
Kwissa M; Unsinger J; Schirmbeck R; Hauser H; Reimann J
J Mol Med (Berl); 2000; 78(9):495-506. PubMed ID: 11140375
[TBL] [Abstract][Full Text] [Related]
5. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
6. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2.
Chow YH; Huang WL; Chi WK; Chu YD; Tao MH
J Virol; 1997 Jan; 71(1):169-78. PubMed ID: 8985336
[TBL] [Abstract][Full Text] [Related]
7. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
8. DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice.
Kuhöber A; Pudollek HP; Reifenberg K; Chisari FV; Schlicht HJ; Reimann J; Schirmbeck R
J Immunol; 1996 May; 156(10):3687-95. PubMed ID: 8621903
[TBL] [Abstract][Full Text] [Related]
9. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the HCV core protein on the immune response to HBV surface antigen and on HBV gene expression and replication in vivo.
Zhu W; Wu C; Deng W; Pei R; Wang Y; Cao L; Qin B; Lu M; Chen X
PLoS One; 2012; 7(9):e45146. PubMed ID: 23024803
[TBL] [Abstract][Full Text] [Related]
12. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.
Yin Y; Wu C; Song J; Wang J; Zhang E; Liu H; Yang D; Chen X; Lu M; Xu Y
PLoS One; 2011; 6(7):e22524. PubMed ID: 21799884
[TBL] [Abstract][Full Text] [Related]
13. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
[TBL] [Abstract][Full Text] [Related]
14. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
15. The doses of plasmid backbone plays a major role in determining the HBV clearance in hydrodynamic injection mouse model.
Wang X; Zhu J; Zhang Y; Li Y; Ma T; Li Q; Xu J; Xu L
Virol J; 2018 May; 15(1):89. PubMed ID: 29783985
[TBL] [Abstract][Full Text] [Related]
16. A novel dendritic-cell-targeting DNA vaccine for hepatitis B induces T cell and humoral immune responses and potentiates the antivirus activity in HBV transgenic mice.
Yu D; Liu H; Shi S; Dong L; Wang H; Wu N; Gao H; Cheng Z; Zheng Q; Cai J; Zou L; Zou Z
Immunol Lett; 2015 Dec; 168(2):293-9. PubMed ID: 26475398
[TBL] [Abstract][Full Text] [Related]
17. Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.
Obeng-Adjei N; Choo DK; Saini J; Yan J; Pankhong P; Parikh A; Chu JS; Weiner DB
Cancer Gene Ther; 2012 Nov; 19(11):779-87. PubMed ID: 23037809
[TBL] [Abstract][Full Text] [Related]
18. Cationic polymers that enhance the performance of HbsAg DNA in vivo.
Bos GW; Kanellos T; Crommelin DJ; Hennink WE; Howard CR
Vaccine; 2004 Dec; 23(4):460-9. PubMed ID: 15530694
[TBL] [Abstract][Full Text] [Related]
19. Routes of plasmid DNA vaccination that prime murine humoral and cellular immune responses.
Böhm W; Mertens T; Schirmbeck R; Reimann J
Vaccine; 1998; 16(9-10):949-54. PubMed ID: 9682342
[TBL] [Abstract][Full Text] [Related]
20. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection.
Du DW; Jia ZS; Li GY; Zhou YY
World J Gastroenterol; 2003 Jan; 9(1):108-11. PubMed ID: 12508362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
